The Berlin-based start-up Cambrium uses artificial intelligence to produce bio-based materials. The materials are sustainable and above all - depending on the use case - adaptable to the respective purpose.
Orphan Diseases and Challenging Targets
Collaborate with venture capital and scientific experts for your drug discovery projects
Connected, comprehensive and always available – the future of health data
Noah Labs, a Berlin and Potsdam-based digital health startup focused on AI-powered telemonitoring for patients with heart failure, has successfully closed a seed funding round of €3 million. Lead investor Nina Capital from Barcelona a dedicated…
Researchers at the Experimental and Clinical Research Center of Max Delbrück Center and Charité – Universitätsmedizin Berlin have found that microbial communities in the mouse GI tract are unevenly distributed, which influences immune cell…
German food fermentation startup Formo has secured $61 million in Series B funding to scale its operations. The round includes existing investors, such as Foodlabs, EQT Ventures, Lowercarbon Capital, Happiness Capital, Elevat3 Capital, M Ventures and…
The role of the adapter protein Picalm in the development of Alzheimer's disease is well known. Now, researchers from the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), the German Center for Diabetes Research (DZD), ETH Zurich, and…
Prof. Christian Gaebler, an HIV researcher at Charité – Universitätsmedizin Berlin, has a goal: to develop treatments that cure HIV infection in patients or prompt the immune system to keep the virus in check in the long term, even without…
Severe systemic lupus no longer detectable after cancer medication treatment
Misha Kudryashev’s lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia. Published in “The EMBO Journal,” the study points to a potentially…
